These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Targeting metabolic reprogramming to overcome drug resistance in advanced bladder cancer: insights from gemcitabine- and cisplatin-resistant models. Kawahara I; Yoshino H; Fukumoto W; Arima J; Saito S; Li G; Fukuda I; Mitsuke A; Sakaguchi T; Inoguchi S; Matsushita R; Nakagawa M; Tatarano S; Yamada Y; Enokida H Mol Oncol; 2024 Sep; 18(9):2196-2211. PubMed ID: 38874588 [TBL] [Abstract][Full Text] [Related]
4. Isocitrate dehydrogenases 2-mediated dysfunctional metabolic reprogramming promotes intestinal cancer progression via regulating HIF-1A signaling pathway. Liu S; Zhou Y; Chen Y; Qiao Y; Bai L; Zhang S; Men D; Zhang H; Pan F; Gao Y; Wang J; Wang Y Int Immunopharmacol; 2024 Oct; 140():112828. PubMed ID: 39094359 [TBL] [Abstract][Full Text] [Related]
5. ROS/PI3K/Akt and Wnt/β-catenin signalings activate HIF-1α-induced metabolic reprogramming to impart 5-fluorouracil resistance in colorectal cancer. Dong S; Liang S; Cheng Z; Zhang X; Luo L; Li L; Zhang W; Li S; Xu Q; Zhong M; Zhu J; Zhang G; Hu S J Exp Clin Cancer Res; 2022 Jan; 41(1):15. PubMed ID: 34998404 [TBL] [Abstract][Full Text] [Related]
6. Hypoxia-induced autophagy promotes gemcitabine resistance in human bladder cancer cells through hypoxia-inducible factor 1α activation. Yang X; Yin H; Zhang Y; Li X; Tong H; Zeng Y; Wang Q; He W Int J Oncol; 2018 Jul; 53(1):215-224. PubMed ID: 29693166 [TBL] [Abstract][Full Text] [Related]
7. Hypoxia-inducible factor 1 promotes chemoresistance of lung cancer by inducing carbonic anhydrase IX expression. Sowa T; Menju T; Chen-Yoshikawa TF; Takahashi K; Nishikawa S; Nakanishi T; Shikuma K; Motoyama H; Hijiya K; Aoyama A; Sato T; Sonobe M; Harada H; Date H Cancer Med; 2017 Jan; 6(1):288-297. PubMed ID: 28028936 [TBL] [Abstract][Full Text] [Related]
8. Gemcitabine and mitomycin induced autophagy regulates cancer stem cell pool in urothelial carcinoma cells. Ojha R; Jha V; Singh SK Biochim Biophys Acta; 2016 Feb; 1863(2):347-59. PubMed ID: 26658162 [TBL] [Abstract][Full Text] [Related]
9. Hypoxia regulates ABCG2 activity through the activivation of ERK1/2/HIF-1α and contributes to chemoresistance in pancreatic cancer cells. He X; Wang J; Wei W; Shi M; Xin B; Zhang T; Shen X Cancer Biol Ther; 2016; 17(2):188-98. PubMed ID: 26785721 [TBL] [Abstract][Full Text] [Related]
10. Impairment of HIF-1α-mediated metabolic adaption by NRF2-silencing in breast cancer cells. Lee S; Hallis SP; Jung KA; Ryu D; Kwak MK Redox Biol; 2019 Jun; 24():101210. PubMed ID: 31078780 [TBL] [Abstract][Full Text] [Related]
11. Metabolic dysregulation and emerging therapeutical targets for hepatocellular carcinoma. Du D; Liu C; Qin M; Zhang X; Xi T; Yuan S; Hao H; Xiong J Acta Pharm Sin B; 2022 Feb; 12(2):558-580. PubMed ID: 35256934 [TBL] [Abstract][Full Text] [Related]
12. Reprogramming metabolism by histone methyltransferase NSD2 drives endocrine resistance via coordinated activation of pentose phosphate pathway enzymes. Wang J; Duan Z; Nugent Z; Zou JX; Borowsky AD; Zhang Y; Tepper CG; Li JJ; Fiehn O; Xu J; Kung HJ; Murphy LC; Chen HW Cancer Lett; 2016 Aug; 378(2):69-79. PubMed ID: 27164560 [TBL] [Abstract][Full Text] [Related]
13. Rg3 inhibits gemcitabine-induced lung cancer cell invasiveness through ROS-dependent, NF-κB- and HIF-1α-mediated downregulation of PTX3. Ahmmed B; Kampo S; Khan M; Faqeer A; Kumar SP; Yulin L; Liu JW; Yan Q J Cell Physiol; 2019 Jul; 234(7):10680-10697. PubMed ID: 30628067 [TBL] [Abstract][Full Text] [Related]
14. HBXIP drives metabolic reprogramming in hepatocellular carcinoma cells via METTL3-mediated m6A modification of HIF-1α. Yang N; Wang T; Li Q; Han F; Wang Z; Zhu R; Zhou J J Cell Physiol; 2021 May; 236(5):3863-3880. PubMed ID: 33305825 [TBL] [Abstract][Full Text] [Related]
15. Wild-type IDH2 is a therapeutic target for triple-negative breast cancer. Li JJ; Yu T; Zeng P; Tian J; Liu P; Qiao S; Wen S; Hu Y; Liu Q; Lu W; Zhang H; Huang P Nat Commun; 2024 Apr; 15(1):3445. PubMed ID: 38658533 [TBL] [Abstract][Full Text] [Related]
16. Hypoxia regulates the expression and localization of CCAAT/enhancer binding protein α by hypoxia inducible factor-1α in bladder transitional carcinoma cells. Xue M; Li X; Chen W Mol Med Rep; 2015 Aug; 12(2):2121-7. PubMed ID: 25824695 [TBL] [Abstract][Full Text] [Related]
17. Overcoming cisplatin resistance of ovarian cancer cells by targeting HIF-1-regulated cancer metabolism. Ai Z; Lu Y; Qiu S; Fan Z Cancer Lett; 2016 Apr; 373(1):36-44. PubMed ID: 26801746 [TBL] [Abstract][Full Text] [Related]
18. UCHL1-HIF-1 axis-mediated antioxidant property of cancer cells as a therapeutic target for radiosensitization. Nakashima R; Goto Y; Koyasu S; Kobayashi M; Morinibu A; Yoshimura M; Hiraoka M; Hammond EM; Harada H Sci Rep; 2017 Jul; 7(1):6879. PubMed ID: 28761052 [TBL] [Abstract][Full Text] [Related]
19. MiR-3662 suppresses hepatocellular carcinoma growth through inhibition of HIF-1α-mediated Warburg effect. Chen Z; Zuo X; Zhang Y; Han G; Zhang L; Wu J; Wang X Cell Death Dis; 2018 May; 9(5):549. PubMed ID: 29748591 [TBL] [Abstract][Full Text] [Related]
20. Role of the MUC1-C oncoprotein in the acquisition of cisplatin resistance by urothelial carcinoma. Shigeta K; Hasegawa M; Kikuchi E; Yasumizu Y; Kosaka T; Mizuno R; Mikami S; Miyajima A; Kufe D; Oya M Cancer Sci; 2020 Oct; 111(10):3639-3652. PubMed ID: 32677159 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]